Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review paper discusses the effectiveness of repurposed drugs and potential novel therapies for treating COVID-19, highlighting remdesivir as the only FDA-approved medication and listing others with Emergency Use Authorization.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

In this study, researchers developed a new Supported Ionic Liquid Phase palladium catalyst that showed effectiveness in aminocarbonylation reactions for synthesizing pharmaceutical compounds like CX-546 and a precursor of Finasteride, though results were sensitive to substrate variations and prompted palladium leaching concerns.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Farudodstat may help treat alopecia areata by protecting hair follicles.

This study found that targeting CISD1 with the compound NL-1 reduced mitochondrial dysfunction and reactive oxygen species accumulation, protecting against cisplatin-induced hearing loss in cell models and mice, without affecting cisplatin's cancer-fighting effectiveness.

This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.

This study introduced hydrogel microneedles loaded with palladium nanoparticles, which utilize the inherent cytotoxicity of polyethyleneimine to enhance the effectiveness of doxorubicin in treating melanoma, achieving a tumor inhibition rate of up to 98% in a murine model.

This review discusses how certain genetic, infectious, and metabolic conditions might influence disease severity and highlights the potential for new therapies, but it presents no new research findings.

This study reported that the PrrH sRNA in *Pseudomonas aeruginosa* may directly regulate genes involved in pyochelin siderophore biosynthesis, highlighting its role in adapting to heme availability, with light conditions influencing this gene expression.

This study reviews current systemic treatments for hidradenitis suppurativa, highlighting traditional methods and new options like biological agents, and suggests that pharmacological therapies show promise, particularly for non-advanced cases, despite the disease's complex etiology involving factors such as genetics and inflammation.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This study suggests that berberine may offer multiple benefits for women with polycystic ovary syndrome by improving metabolic and hormonal profiles, though further research is needed on its long-term effects on reproductive outcomes.

In this study, the researchers reported that a newly developed PYGL inhibitor, HTPI, enhanced hair growth in an ex-vivo culture by reducing oxidative damage in hDPCs and inhibiting glycogen degradation in hORSCs, showing potential as a treatment for hair loss comparable to minoxidil.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This study identified certain benzopyran derivatives with a bulky tert-butyloxycarbonylamino group as effective KATP channel openers that inhibit insulin secretion in rat pancreatic islets.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This study suggests that specific structural features of minoxidil analogs, such as hydrophobic and hydrogen bond field contributions, are key to enhancing lysyl hydroxylase inhibitory activity, which could inform future hair growth treatments.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

This study found that DC-HIL+ myeloid derived suppressor cells are increased in the blood and skin of patients with cutaneous lupus erythematosus and show immunosuppressive properties.

This study found that regio-specific hydroxylation of cyclosporine A in Sebekia benihana is mediated by the cytochrome P450 hydroxylase CYP-sb21, suggesting potential biotechnological applications for hair growth promotion without immunosuppressive effects.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This study found that epidermal growth factor receptor and mitogen activated protein kinase inhibitors down-regulate PD-L1 expression in human hair follicles, which may contribute to sterile folliculitis in treated patients.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

This study suggests that activating the PPARs/SHH-mitochondrial axis may enhance diabetic wound healing by improving endothelial cell metabolism and angiogenesis, indicating potential for PPAR agonists in treating diabetic foot ulcers.

This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.

This review discusses strategies for treating hormone-dependent prostate diseases and synthesizes a range of potential 5α-reductase inhibitors, but experimental evaluation of these compounds was not completed.